<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270071</url>
  </required_header>
  <id_info>
    <org_study_id>YXSM_2019001</org_study_id>
    <nct_id>NCT04270071</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris</brief_title>
  <official_title>Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris: Randomised, Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, parallel clinical trial in
      Chinese population with stable angina pectoris. The purpose is to determine the efficacy and
      safety of Yangxin Shengmai Granules in the treatment of stable angina pectoris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Yangxin Shengmai granules is a Chinese patent medicine composed of ginseng, Ophiopogon
      japonicus, Salvia miltiorrhiza, Schisandra chinensis, etc. It is used for the treatment of
      chest pain caused by Qi-yin deficiency and blood stasis in traditional Chinese medicine. The
      symptoms include chest tightness, chest pain, palpitation, shortness of breath, fatigue, dry
      mouth and dry throat. Clinical applications suggested that Yangxin Shengmai granules were
      safe and effective in the treatment of coronary heart disease. However, high-quality clinical
      trials are still needed to further confirm, so as to provide theoretical basis for the
      treatment of stable angina pectoris with traditional Chinese medicine.

      The study is designed to determine the efficacy and safety of Yangxin Shengmai Granules in
      the treatment of stable angina pectoris.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stopping or reducing rate of the nitroglycerin tablets</measure>
    <time_frame>Four weeks after treatment</time_frame>
    <description>Number of nitroglycerin tablets used before medication - number of nitroglycerin tablets used after medication) / number of nitroglycerin tablets used before medication × 100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of angina symptom score</measure>
    <time_frame>Two and four weeks after treatment</time_frame>
    <description>Calculate results according to angina symptom integral table</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes in coronary heart disease</measure>
    <time_frame>Two and four weeks after treatment</time_frame>
    <description>Tgrough clinical outcome evaluation scale for patients with coronary heart disease with angina pectoris</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Yangxin Shengmai Granules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were given Yangxin Shengmai granules orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.
For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were given Yangxin Shengmai granules simulation orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.
For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yangxin Shengmai</intervention_name>
    <description>Yangxin Shengmai Granules</description>
    <arm_group_label>Yangxin Shengmai Granules</arm_group_label>
    <other_name>YXSM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yangxin Shengmai placebo</intervention_name>
    <description>Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>YXSM placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitroglycerin tablets</intervention_name>
    <description>Be used when angina attack</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Yangxin Shengmai Granules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are aged between 40 and 75 years.

          -  Meet the diagnostic criteria of stable angina pectoris.

          -  Meet Chinese medicine syndrome differentiation of Qi-yin deficiency and blood stasis
             syndrome.

          -  Voluntarily participate and sign informed consent.

        Exclusion Criteria:

          -  Patients were diagnosed as acute myocardial infarction, unstable angina, stable
             exertion angina and other heart diseases.

          -  Patients with poor control of hypertension and diabetes, severe cardiopulmonary
             insufficiency, severe arrhythmia (rapid atrial fibrillation, atrial flutter,
             paroxysmal ventricular tachycardia, etc.), with a history of heart pacemaker or
             cerebrovascular disease within one year.

          -  Any of the following disease history or evidence was found in the screening period:
             severe cardiovascular or cerebrovascular diseases; active, recurrent peptic ulcer or
             other bleeding risk diseases; other serious diseases of digestive system; combined
             with malignant tumor, blood system disease, serious or progressive diseases of the
             other system; combined with mental diseases.

          -  Before screening, any laboratory inspection index meets the following standards: The
             results showed that Glutamic aspartate transaminase (AST) or alanine aminotransferase
             (ALT) were more than 1.5 times of the upper limit of normal value and serum creatinine
             (Cr) was more than 1.2 times of the upper limit of normal value.

          -  With a history of alcohol and drug abuse.

          -  Pregnant or lactating women.

          -  Patients who have participated in clinical trials of other drugs within 3 months
             before enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, MD</last_name>
    <phone>+86 13051458913</phone>
    <email>gamyylj@163.com</email>
  </overall_contact>
  <reference>
    <citation>Liu S, Tian G, Chen J, Zhang X, Wu A, Li M, Sun Y, Liu B, Xing Y, Shang H. Traditional Chinese Medicine for Bradyarrhythmia: Evidence and Potential Mechanisms. Front Pharmacol. 2018 Apr 9;9:324. doi: 10.3389/fphar.2018.00324. eCollection 2018.</citation>
    <PMID>29686614</PMID>
  </reference>
  <results_reference>
    <citation>Walters MA. Management of Chronic Stable Angina. Crit Care Nurs Clin North Am. 2017 Dec;29(4):487-493. doi: 10.1016/j.cnc.2017.08.008. Epub 2017 Sep 29. Review.</citation>
    <PMID>29107310</PMID>
  </results_reference>
  <results_reference>
    <citation>Kallistratos MS, Poulimenos LE, Manolis AJ. Beta blockers, calcium channel blockers, and long-acting nitrates for patients with stable angina and low blood pressure levels: should this recommendation be reconsidered? Eur Heart J. 2020 Jan 14;41(3):479. doi: 10.1093/eurheartj/ehz900.</citation>
    <PMID>31883335</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen M, Men L, Wu H, Zhong G, Ou L, Li T, Guo Y, Lin H, Zhang J, Wang D, Zhang Z. A systematic review of the effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris. Medicine (Baltimore). 2019 Dec;98(51):e18375. doi: 10.1097/MD.0000000000018375.</citation>
    <PMID>31860998</PMID>
  </results_reference>
  <results_reference>
    <citation>Li Y, Zhang L, Lv S, Wang X, Zhang J, Tian X, Zhang Y, Chen B, Liu D, Yang J, Dong P, Xu Y, Song Y, Shi J, Li L, Wang X, Han Y. Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial. BMC Complement Altern Med. 2019 Dec 11;19(1):363. doi: 10.1186/s12906-019-2778-z.</citation>
    <PMID>31829173</PMID>
  </results_reference>
  <results_reference>
    <citation>Surveillance report 2016 – Stable angina: management (2011) NICE guideline CG126 [Internet]. London: National Institute for Health and Care Excellence (UK); 2016 Apr 3. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK551066/</citation>
    <PMID>31855330</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang X, He T, Han S, Zhang X, Sun Y, Xing Y, Shang H. The Role of Traditional Chinese Medicine in the Regulation of Oxidative Stress in Treating Coronary Heart Disease. Oxid Med Cell Longev. 2019 Feb 24;2019:3231424. doi: 10.1155/2019/3231424. eCollection 2019. Review.</citation>
    <PMID>30918578</PMID>
  </results_reference>
  <results_reference>
    <citation>Gong P, Li Y, Yao C, Guo H, Hwang H, Liu X, Xu Y, Wang X. Traditional Chinese Medicine on the Treatment of Coronary Heart Disease in Recent 20 Years. J Altern Complement Med. 2017 Sep;23(9):659-666. doi: 10.1089/acm.2016.0420. Epub 2017 May 12. Review.</citation>
    <PMID>28497986</PMID>
  </results_reference>
  <results_reference>
    <citation>Li GH, Jiang HY, Xie YM, Jiang JJ, Yang W, Zhao W, Zhuang Y, Wang YY. [Analysis of traditional Chinese medicine syndrome, traditional Chinese medicine and western medicine in 84 697 patients with coronary heart disease based on big data]. Zhongguo Zhong Yao Za Zhi. 2014 Sep;39(18):3462-8. Chinese.</citation>
    <PMID>25532378</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun Li</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>Yangxinshengmai granules</keyword>
  <keyword>Stable angina pectoris</keyword>
  <keyword>Coronary heart disease</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

